Pfizer, Atavistik
Atavistik Bio Announces Research Collaboration with Pfizer to Accelerate Discovery of Novel Precision Allosteric Therapeutics
Collaboration will leverage Atavistik Bio’s proprietary AMPS™ platform to rapidly identify and validate novel allosteric binders against two undisclosed, Pfizer-designated targetsAtavistik Bio has rapidly identified novel,
Atavistik Bio collaborates with Pfizer to discover allosteric therapeutics
Atavistik Bio Inc. has entered into a research collaboration with Pfizer Inc. to accelerate the discovery of novel precision allosteric therapeutics for unmet medical needs. Under the collaboration, Atavistik Bio will leverage its proprietary AMPS platform to identify novel allosteric binders against two undisclosed targets selected by Pfizer.
This partnership could redefine precision medicine with groundbreaking therapeutics targeting "impossible" proteins.
Join 80+ technical experts from the likes of AstraZeneca, Atavistik Bio, AbbVie, NextRNA Therapeutics, Expansion Therapeutics, Accent Therapeutics and more at the 2nd RNA Assay Development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback